natgillin/translations-raw huggingface dataset:
100 AMPOULES WITH 2 ML
100 AMPULA S 2 ML
100 ampoules: solvent
100 ampula: otapalo
100 capsules
100 kapsule
100 capsules
EU/1/15/1012/054
100 coated tablets
100 obloženih tableta
100 day (for HDPE 100’s count)
100 dana (za HDPE sa 100 tableta)
100 day (for HDPE 200’s count)
100 dana (za HDPE bočice s 200 kapsula)
100 dispersible tablets
100 tableta za oralnu suspenziju
100 doses (100 ml)
100 doza (100 ml).
100 exposure days.
100 dana izloženosti.
100 film coated tablets
100 filmom obloženih tableta
100 film-coated tablets
30 filmom obloženih tableta 100 filmom obloženih tableta
100 film-coated tablets (HDPE Bottle)
100 filmom obloženih tableta (HDPE boca)
100 film-coated tablets 10x1 film-coated tablets 14x1 film-coated tablets 28x1 film-coated tablets 30x1 film-coated tablets 56x1 film-coated tablets 100x1 film-coated tablets
100 filmom obloženih tableta 10x1 filmom obložena tableta 14x1 filmom obložena tableta 28x1 filmom obložena tableta 30x1 filmom obložena tableta 56x1 filmom obložena tableta 100x1 filmom obložena tableta
100 film-coated tablets 28x1 film-coated tablets 50x1 film-coated tablets
28x1 filmom obloženih tableta 50x1 filmom obloženih tableta
100 film-coated tablets.
100 filmom obloženih tableta
100 film-coated tablets.
100 filmom obloženih tableta.
100 hard gastro-resistant capsules (5 cartons of 20 capsules) 500 hard gastro-resistant capsules (25 cartons of 20 capsules)
100 tvrdih želučanootpornih kapsula (5 kutija po 20 kapsula) 500 tvrdih želučanootpornih kapsula (25 kutija po 20 kapsula)
100 international units insulin human (30% as soluble insulin and 70% as isophane insulin) (equivalent to 3.5 mg),
100 internacionalnih jedinica humanog inzulina (30% otopine inzulina i 70% izofan inzulina) (što odgovara 3,5 mg),
100 international units soluble insulin human*/isophane (NPH) insulin human* in the ratio 30/70 (equivalent to 3.5 mg).
100 internacionalnih jedinica otopine humanog inzulina*/humanog izofan (NPH) inzulina* u omjeru 30/70 (što odgovara 3,5 mg).
100 international units soluble insulin human*/isophane (NPH) insulin human* in the ratio 40/60 (equivalent to 3.5 mg).
100 internacionalnih jedinica otopine humanog inzulina*/humanog izofan (NPH) inzulina* u omjeru 40/60 (što odgovara 3,5 mg).
100 international units soluble insulin human*/isophane (NPH) insulin human* in the ratio 50/50 (equivalent to 3.5 mg).
100 internacionalnih jedinica otopine humanog inzulina*/humanog izofan (NPH) inzulina* u omjeru 50/50 (što odgovara 3,5 mg).
100 IU (200 IU/mL) recombinant follicle-stimulating hormone (FSH) activity.
100 IU (200 IU/ml) aktivnosti rekombinantnog folikulostimulirajućeg hormona (FSH).
100 IU per ml and 40 IU per ml) must not be mixed.
100 IU/ml i 40 IU/ml).
100 IU/kg once every 10 days, adjust interval based on individual response.
100 IU/kg jedanput svakih 10 dana, uz prilagodbu vremenskog razmaka između doza na temelju odgovora pojedinog bolesnika.
100 IU/ml after reconstitution).
100 IU/ml nakon pripreme).
100 mcg/0.3 ml
100 mcg/0,3 ml
100 mg
100 m
100 mg
za 100 mg
100 mg (1 orange 80 mg capsule and 1 grey 20 mg capsule)
100 mg (1 narančasta kapsula od 80 mg i 1 siva kapsula od 20 mg)
100 mg (2.5 ml) twice daily
100 mg (2,5 ml) dvaput na dan
100 mg (N = 157)
100 mg (N=157)
100 mg (N = 368)
100 mg (N=368)
100 mg (N = 566)
100 mg (N=566)
100 mg / 10 mL
100 mg/10 ml
100 mg / day*
100 mg na dan
100 mg /day (in two divided doses)
100 mg na dan (podijeljeno u dvije doze)
100 mg capsules
Kapsule od 100 mg
100 mg cream contains 5 mg imiquimod
100 mg kreme sadržava 5 mg imikvimoda.
100 mg daily
100 mg na dan
100 mg daily + Victrelis 800 mg
100 mg na dan + Victrelis 800 mg
100 mg daily taken as 50 mg in the morning and 50 mg in the evening if you are taking Galvus alone, with another medicine called metformin or a glitazone, with a combination of metformin and a sulphonylurea, or with insulin.
100 na dan, što se uzima kao doza od 50 mg ujutro i 50 mg navečer ako uzimate Galvus sam ili s drugim lijekom koji se zove metformin ili glitazon, u kombinaciji s metforminom i sulfonilurejom ili inzulinom.
100 mg daily taken as 50 mg in the morning and 50 mg in the evening if you are taking Jalra alone, with another medicine called metformin or a glitazone, with a combination of metformin and a sulphonylurea, or with insulin.
100 na dan, što se uzima kao doza od 50 mg ujutro i 50 mg navečer ako uzimate Jalru sam ili s drugim lijekom koji se zove metformin ili glitazon, u kombinaciji s metforminom i sulfonilurejom ili inzulinom.
100 mg daily taken as 50 mg in the morning and 50 mg in the evening if you are taking Xiliarx alone, with another medicine called metformin or a glitazone, with a combination of metformin and a sulphonylurea, or with insulin.
100 na dan, što se uzima kao doza od 50 mg ujutro i 50 mg navečer ako uzimate Xiliarx sam ili s drugim lijekom koji se zove metformin ili glitazon, u kombinaciji s metforminom i sulfonilurejom ili inzulinom.
100 mg film-coated tablets: polyvinyl alcohol, titanium dioxide (E171), macrogol 3350, talc, iron oxide yellow (E172), iron oxide black (E172).
100 mg filmom obložene tablete: poli(vinilni) alkohol, titanijev dioksid (E171), makrogol 3350, talk, žuti željezov oksid (E172), crni željezov oksid (E172)
100 mg once a day
100 mg jednom dnevno
100 mg once daily (n=315)
Sitagliptin 100 mg jedanput na dan (n=315)
100 mg once daily, Cmax is in the order of 1.1-1.5 µg/ml and trough levels were 0.015-0.020 µg/ml.
100 mg jedanput na dan, Cmax se kreće u vrijednostima od 1,1 do 1,5 µg/ml dok su najniže koncentracije lijeka 0,015-0,020 µg/ml.
100 mg once daily, Cmax is in the order of 1.1-1.5 µg/ml and trough levels were 0.015-0.020 µg/ml.
100 mg jednom na dan, Cmax se kreće u vrijednostima od 1,1 do 1,5 µg/ml dok su najniže koncentracije lijeka 0,015-0,020 µg/ml.
100 mg Outer Carton
Synagis 100 mg vanjska kutija
100 mg prednisolone
100 mg prednizolon
100 mg prednisolone (3 g sachet)
100 mg prednizolon (3 g vrećica)
100 mg QD1
100 mg jednom dnevno1
100 mg single-use vial containing powder for concentrate for infusion solution delivers 5 mL of 20 mg/mL of trastuzumab emtansine after reconstitution (see section 6.6).
Jedna bočica za jednokratnu uporabu sadrži 100 mg praška za koncentrat za otopinu za infuziju kojim se nakon rekonstitucije dobiva 5 ml trastuzumab emtanzina koncentracije 20 mg/ml (vidjeti dio 6.6).
100 mg single-use vial containing powder for concentrate for infusion solution delivers 5 mL of 20 mg/mL of trastuzumab emtansine after reconstitution.
Jedna bočica za jednokratnu uporabu sadrži 100 mg praška za koncentrat za otopinu za infuziju kojim se nakon pripreme za primjenu dobiva 5 ml trastuzumab emtanzina koncentracije 20 mg/ml.
100 mg suspension for injection
100 mg suspenzija za injekciju
100 mg tablet
tableta 100 mg
100 mg tablets:
Tablete od 100 mg:
100 mg three times a day
100 mg triput dnevno
100 mg trastuzumab emtansine vial: Using a sterile syringe, slowly inject 5 mL of sterile water for injection into the vial.
Bočica sa 100 mg trastuzumab emtanzina: Sterilnom štrcaljkom polako ubrizgajte 5 ml sterilne vode za injekcije u bočicu.
100 mg twice a day
100 mg dvaput na dan
100 mg twice daily
100 mg dvaput dnevno
100 mg twice daily over 6 month interval in Study 2 and numerically higher than placebo in Study 1.
100 mg dvaput na dan tijekom razdoblja od 6 mjeseci u Ispitivanju 2 i brojčano viši nego placebo u Ispitivanju 1.
100 mg valnemulin base per 1 g
100 mg baze valnemulina po 1 g
100 mg vial has a shelf life of 3 years.
Bočica sa 100 mg ima rok valjanosti 3 godine.
100 mg, both administered
ritonavira od 100 mg,
100 mg/ 25 mg tablets – Carton of 1 bottle
100 mg/ 25 mg tablete – Kutija s 1 bocom
100 mg/25 mg tablets - bottle label
100 mg/25 mg tablete – naljepnica na boci
100 mg/25 mg tablets may be used.
100 mg/25 mg tablete.
100 mg/25 mg/200 mg or 125 mg/31.25 mg/200 mg or 150 mg/37.5 mg/200 mg or
75 mg/18,75 mg/200 mg ili 100 mg/25 mg/200 mg ili 125 mg/31,25 mg/200 mg ili 150 mg/37,5 mg/200 mg ili 175 mg/43,75 mg/200 mg) tabletama, doziranje
100 mg/25 mg/200 mg, 125 mg/31.25 mg/200 mg and 150 mg/37.5 mg/200 mg.
100 mg/25 mg/200 mg, 125 mg/31,25 mg/200 mg i 150 mg/37,5 mg/200 mg.
100 mg/day (in
100 mg na dan
100 mg/day*
100 mg na dan
100 mg/kg (treatment on gestation days 20-50) and have revealed no evidence of toxicity to the foetus due to rituximab.
100 mg/kg (primjena od 20. do 50. dana gestacije) nisu pokazala znakove toksičnosti za fetus koju bi uzrokovao rituksimab.
100 mg/m² administered as a 30-minute to three-hour intravenous infusion, followed by the continuous intravenous infusion of 5-fluorouracil (F) 1000 mg/m²/day from day 1 to day 4.
100 mg/m2 primijenjen kao 30-minutna do 3-satna intravenska infuzija praćena kontinuiranom intravenskom infuzijom 5-fluorouracila (F) 1000 mg/m2 dnevno od dana 1 do dana 4.
100 mg/m² administered as a 30-minute to three-hour intravenous infusion, followed by the continuous intravenous infusion of 5-fluorouracil (F) 1000 mg/m²/day from day 1 to day 4.
75 mg/m2 intravenskom. infuzijom na dan 1 nakon čega je slijedio cisplatin (P) 100 mg/m2 primijenjen kao 30-minutna do 3-satna intravenska infuzija praćena kontinuiranom intravenskom infuzijom 5- fluorouracila (F) 1000 mg/m2 dnevno od dana 1 do dana 4.
100 mg/tenofovir 300 mg once daily,
100 mg/tenofovir 300 mg jedanput
100 mg: 56 and 98 orodispersible tablets
100 mg: 56 i 98 raspadljivih tableta za usta
100 micrograms
100 mikrograma
100 micrograms / dose
100 mikrograma / doza
100 micrograms fentanyl (as citrate)
100 mikrograma fentanila (u obliku fentanilcitrata)
100 micrograms labelling is purple
100 mikrograma označeno je ljubičasto
100 micrograms PRE-FILLED SYRINGES LABEL
NALJEPNICA ZA NAPUNJENU ŠTRCALJKU 100 mikrograma
100 micrograms/dose labelling is purple
100 mikrograma/doza, označeno je ljubičasto
100 milligram
100 miligrama
100 milligram of ritonavir two times per day or 800 milligram PREZISTA together with
100 miligrama ritonavira dva puta na dan ili 800 miligrama lijeka PREZISTA zajedno sa
100 milligram ritonavir once a day.
100 miligrama ritonavira jedanput na dan.
100 milligram ritonavir two times per day or 800 milligram PREZISTA together with 100 milligram ritonavir once a day.
100 miligrama ritonavira dva puta na dan ili 800 miligrama lijeka PREZISTA zajedno sa 100 miligrama ritonavira jedanput na dan.
100 ml
10 x 100 ml
100 ml
IU/3 ml
100 ml
Otapalo: 100 ml
100 ml (1 measuring syringe)
100 ml (1 mjerna štrcaljka)
100 ml (100 doses)
100 ml (100 doza)
100 ml (50 doses)
100 ml (50 doza)
100 ml (50 doses)
100 ml (50 doza).
100 ml (50 doses) 200 ml (100 doses) 250 ml (125 doses)
20 ml (10 doza) 50 ml (25 doza) 100 ml (50 doza) 200 ml (100 doza) 250 ml (125 doza)
100 ml (50 doses) 250 ml (125 doses)
100 ml (50 doza) 250 ml (125 doza)
100 ml 100 % orange juice
100 ml 100%-tnog soka od naranče
100 ml amber glass bottle (with child-resistant polypropylene screw cap, outer part: polyethylene; inner part: polypropylene; liner: polyethylene) with 30 g of powder for oral suspension, a plastic adapter (low density polyethylene), a plastic oral dispenser (30 mg, 45 mg and 60 mg graduation) (barrel and plunger: polypropylene; silicon based seal ring) and a plastic measuring cup (polypropylene).
Staklena boca jantarne boje od 100 ml (zatvorena polipropilenskim sigurnosnim zatvaračem za djecu, vanjski dio: polietilen; unutarnji dio: polipropilen; obloga: polietilen) s 30 g praška za oralnu suspenziju, plastični nastavak za bocu (polietilen niske gustoće), plastična štrcaljka za usta (s graduacijom za 30 mg, 45 mg i 60 mg) (tijelo i klip: polipropilen; silikonski zaštitni prsten) te plastična odmjerna čašica (polipropilen).
100 ml and 250 ml HDPE bottles
100 ml i 250 ml HDPE bočice
100 ml Cyclic Olefin Polymer (COP) plastic bottle, fitted with a chlorobutyl/butyl rubber stopper and aluminium cap fitted with blue plastic flip off disc.
100 ml u plastičnoj (cikloolefinski kopolimer) boci s klorobutil/butilnim čepom i aluminijskim zatvaračem s plavom plastičnom „flip-off“ pločicom.
100 ml Cyclic Olefin Polymer (COP) plastic bottle, fitted with a chlorobutyl/butyl rubber stopper and aluminium cap fitted with violet plastic flip off disc.
Plastična bočica od cikloolefinskog polimera (COP) volumena 100 ml, s klorobutil/butilnim gumenim čepom i aluminijskom kapicom s ljubičastim plastičnim flip off diskom.
100 ml infusion bags should be considered for patients who are susceptible to fluid volume overload and weigh less than 20 kg; in this case the infusion rate (ml/min) should be decreased so that the total duration remains no less than 4 hours.
Za bolesnike koji su osjetljivi na volumno preopterećenje tekućinom i imaju manje od 20 kg treba koristiti infuzijske vrećice od 100 ml; u tom slučaju brzina infuzije (ml/min) mora se smanjiti tako da ukupno trajanje ne bude manje od 4 sata.
100 ml multilayer polyolefin/styrene-ethylene-butylene (SEB) bag with SFC polypropylene infusion port closed with rubber stopper and snap cap.
Višeslojna poliolefin/stiren-etilen-butilen (SEB) vrećica od 100 ml sa SFC polipropilenskim infuzijskim otvorom zatvorenim gumenim čepom i kapicom.
100 ml plastic bottle
Plastična bočica od 100 ml
100 ml polypropylene bags with a polypropylene twist-off port fitted with a cap, with a polyester/polypropylene overwrap
Polipropilenska vrećica od 100 ml s polipropilenskim zatvaračem s pričvršćenim poklopcem, s poliesterskim/polipropilenskim omotom.
100 ml solution in colourless glass bottle type I with fluoropolymer coated halobutyl rubber stopper and aluminium flip-off cap.
Boca od bezbojnog stakla tipa i sa 100 ml otopine, s čepom od halobutilne gume obloženim fluoropolimerom i aluminijskim „flip-off“ poklopcem.
100 ml) final
završna koncentracija
100 mL/hour
1000 ml/h
100 out of 929 patients (10.8%) with solid tumours were described as having an infusion-associated reaction during treatment with Caelyx as defined by the following Costart terms: allergic reaction, anaphylactoid reaction, asthma, face oedema, hypotension, vasodilatation, urticaria, back pain, chest pain, chills, fever, hypertension, tachycardia, dyspepsia, nausea, dizziness, dyspnoea, pharyngitis, rash, pruritus, sweating, injection site reaction and medicinal product interaction.
Tijekom liječenja Caelyxom, u 100 od 929 bolesnika (10,8%) sa solidnim tumorima prijavljene su reakcije povezane s infuzijom definirane u skladu sa sljedećim Costart izrazima: alergijska reakcija, anafilaktoidna reakcija, astma, edem lica, hipotenzija, vazodilatacija, urtikarija, križobolja, bol u prsištu, zimice, vrućica, hipertenzija, tahikardija, dispepsija, mučnina, vrtoglavica, dispneja, faringitis, osip, svrbež, znojenje, reakcije na mjestu primjene injekcije i interakcije s lijekovima.
100 patient years of use.
0,8 prijeloma na 100 bolesnik-godina primjene.
100 patient-years of follow-up for ustekinumab-treated patients (1 patient in 829 patient-years of follow-up) compared with 0.26 for placebo-treated patients (1 patient in 385 patient-years of follow-up).
100 bolesnik-godina praćenja bolesnika liječenih ustekinumabom (1 bolesnik na 829 bolesnik-godina praćenja) u usporedbi s 0,26 bolesnika u placebo grupi (1 bolesnik na 385 bolesnik-godina praćenja).
100 patients [(naïve (n=29); or previously treated with agalsidase beta who switched to Replagal (n=71)) were treated for up to 30 months in an open label, uncontrolled study.
100 bolesnika [prethodno neliječenih (n=29) ili prethodno liječenih agalzidazom beta koji su prešli na Replagal (n=71)] liječena su do 30 mjeseci u otvorenom, nekontroliranom ispitivanju.
100 pre-filled syringes
100 napunjenih štrcaljki
100 prolonged-release tablets
100 tableta s produljenim oslobađanjem
100 q12h
100 svakih 12h
100 tablets
) 100 tableta
100 tablets
100 mg
100 tablets
100 tablet
100 tablets
12 tableta
100 tablets
3 tablete
100 tablets
30 tableta
100 tablets
6 tableta
100 tablets
premnik za tablete
100 tablets
tableta
100 tablets (2 X 50)
100 tableta (2 x 50)
100 tablets bottle: 100 days
Bočica sa 100 tableta: 100 dana
100 tablets: EU/1/08/469/005
100 tableta: EU/1/08/469/005
100 tablets: EU/1/08/469/010
100 tableta: EU/1/08/469/010
100 tablets: EU/1/08/469/015
100 tableta: EU/1/08/469/015
100 tablets: EU/1/08/469/020
100 tableta: EU/1/08/469/020
100 tablets: EU/1/08/469/025
100 tableta: EU/1/08/469/025
100 tablets: EU/1/10/632/022
100 tableta: EU/1/10/632/022
100 tablets: EU/1/10/632/023
100 tableta: EU/1/10/632/023
100 tablets: EU/1/10/632/024
100 tableta: EU/1/10/632/024
100 Tasigna 300 mg twice daily (n = 282)
100 Tasigna 300 mg 2xdan (n = 282)
100 to <200 cells/mm3
100 do <200 stanica
100 U/ml (3.5 mg/ml)
100 U/ml (3,5 mg/ml)
100 Units/ml
100 jedinica/ml
100 units/ml (3.5 mg/ml)
100 jedinica/ml (3,5 mg/ml)
100 VIAL AND 100 AMPOULES
100 BOČICA I 100 AMPULA
100 vials
100 bočica
100 vials of lyophylisate and 100 vials of solvent (100 doses)
100 bočica liofilizata i 100 bočica otapala (100 doza)
100 vials: powder
100 bočica: prašak
100 Weeks
100. tjedan
100 x 1
100 x 1 tableta
100 x 1 (Unit dose)
100 x 1 (jedinična doza)
100 x 1 capsules
100 x 1 kapsula
100 x 1 capsules (unit
100 x 1 kapsula
100 x 1 capsules (unit dose)
100 x 1 kapsula (jedinična doza)
100 x 1 capsules (unit dose)
EU/1/15/1011/011
100 x 1 capsules (unit dose)
EU/1/15/1012/018
100 x 1 dose (0.5 ml)
100 x 1 doza (0,5 ml)
100 x 1 film-coated tablet
100 x 1 filmom obložena tableta
100 X 1 film-coated tablet
100 X 1 filmom obloženih tableta
100 x 1 film-coated tablets
100 x 1 filmom obloženih tableta
100 x 1 film-coated tablets.
100 x 1 filmom obložena tableta.
100 x 1 hard capsules
100 x 1 tvrda kapsula
100 x 1 hard gastro-resistant capsules
100 x 1 tvrdih želučanootpornih kapsula
100 x 1 tablet (unit
100 x 1 tableta
100 x 1 tablet (unit dose)
100 x 1 tableta (jedinična doza)
100 x 1 tablets
tableta
100 x 1 tablets (unit dose)
100 x 1 tableta (jedinična doza)
100 x 2 doses (1 ml)
100 x 2 doze (1 ml)
100 µg / spray
100 μg / sprej
100 µg / spray
100 μg/ sprej
100 μg/1ml
100 μg/1 ml
100 – 180 mg
100-180 mg
100% sevoflurane
100% sevofluran
100) is increased liver enzymes.
100) povišeni jetreni enzimi.
100, 200 and 250 ml
100,200 i 250 ml
100-101 Terrasse Boieldieu Tour Franklin- La Défense 8 92042 Paris la Défense Cedex France
100­101 Terrasse Boieldieu Tour Franklin­ La Défense 8 92042 Paris la Défense Cedex Francuska
100-200 mg TID
100-200 mg 3x/dan
100.0 mg ethanol, 455.0 mg macrogolglycerol ricinoleate and 12.6 mg sorbitol
100,0 mg etanola, 455,0 mg makrogolglicerolricinoleata i 12,6 mg sorbitola
100.0)
tipa 16/18
1000 Brussels Belgium
1000 Brussels Belgija
1000 Brussels Belgium
1000 Brussels Belgija mailto:
1000 Brussels Belgium medinfoeuceemea@shire.com
1000 Brussels Belgija medinfoeuceemea@shire.com
1000 doses
1000 doza:
1000 doses (3-100 spheres) 5000 doses (3-100 spheres) 10000 doses (3-100 spheres)
1000 doza (3-100 kuglica) 5000 doza (3-100 kuglica) 10000 doza (3-100 kuglica)
1000 International Units/vial simoctocog alfa (400 IU/ml after reconstitution)
1000 međunarodnih jedinica simoktokog alfa po bočici (400 IU/ml nakon rekonstitucije)
1000 IU
1000 UI
1000 IU (octocog alfa) (400 IU/mL after reconstitution).
1000 IU (oktokoga alfa) (400 IU/ml nakon pripreme za primjenu).
1000 IU human coagulation factor IX (100 IU/ml after reconstitution).
1000 IU ljudskog faktora zgrušavanja IX (100 IU/ml nakon pripreme).
1000 IU moroctocog alfa for single IV use
1000 IU moroktokoga alfa za jednokratnu i.v. primjenu
1000 IU octocog alfa
1000 IU oktokoga alfa
1000 IU octocog alfa (400 IU/ml after reconstitution).
1000 IU oktokoga alfa (400 IU/ml nakon pripreme za primjenu).
1000 IU* human coagulation factor VIII** (FVIII)
1000 IU* ljudskog koagulacijskog faktora VIII** (FVIII)
1000 IU/0.5 ml
1 000 IU/0,5 ml
1000 IU/0.5 ml
1000 IU/0,5 ml
1000 IU/0.5 ml
40000 IU/1 ml
1000 IU/vial
1000 IU po bočici
1000 mg BID
Sakvinavir 1000 mg BID
1000 mg sachets
1000 mg vrećice
1000 mg twice daily increased plasma concentrations of simvastatin lactone, simvastatin acid by about 2 fold.
Ranexa primijenjena u dozi od 1000 mg dvaput dnevno povisila je koncentracije simvastatin laktona u plazmi, simvastatinske kiseline oko 2 puta.
1000 mg twice daily increased plasma concentrations of simvastatin lactone, simvastatin acidby about 2-fold.
Ranexa primijenjena u dozi od 1000 mg dvaput dnevno povisila je koncentracije simvastatin laktona u plazmi, simvastatinske kiseline oko 2 puta.
1000 mg/day
1000 mg/da n
1000 mg/m2
1000 mg/m
1000 mg/m2 oral
1000 mg/m2 oralno dvaput dnevno
1000 mg/m2 oral bid
1000 mg/m2 peroralno dva puta na dan
1000 mg/m2 oral twice daily
1000 mg/m2 oralno dvaput dnevno
1000 mg: 10, 20, 30, 50, 60, 100 and multipack of 200 (2 packs of 100) film-coated tablets.
1000 mg: 10, 20, 30, 50, 60, 100 i višestruka pakiranja od 200 (2 pakiranja od 100) filmom obloženih tableta.
1000 mg: 10, 20, 30, 50, 60, 100 x 1, 100 film-coated tablets and multipacks containing 200 (2 packs of 100) film-coated tablets
1000 mg: 10, 20, 30, 50, 60, 100 x 1, 100 filmom obloženih tableta i višestruka pakiranja koja sadrže 200 (2 pakiranja od 100) filmom obloženih tableta
1000 New Horizons Way Vacaville, CA 95688-9431 USA
1000 New Horizons Way Vacaville, CA 95688-9431 SAD
1000 pigs with an average body weight of 50 kg).
1000 svinja prosječne mase 50 kg).
1000 q12h
1000 svakih 12h
1000 Units of Cinryze at the first sign of the onset of an angioedema attack.
1000 jedinica lijeka Cinryze kod prvog znaka početka napadaja angioedema.
1000 Units of Cinryze every 3 or 4 days is the recommended starting dose for routine prevention against angioedema attacks; the dosing interval may need to be adjusted according to individual response.
Preporučena početna doza za rutinsku prevenciju napadaja angioedema je 1000 jedinica lijeka Cinryze svaka 3 ili 4 dana; vremenski razmak između doza možda će trebati prilagoditi ovisno o odgovoru pojedinog bolesnika.
1000 Units of Cinryze within 24 hours before a medical, dental, or surgical procedure.
1000 jedinica lijeka Cinryze unutar 24 sata prije medicinskog, zubarskog ili kirurškog zahvata.
1000 – 10,000 copies/ml
1 000 – 10 000 kopija/ml
1000 – 10,000 copies/ml
1000 – 10 000 kopija/ml
1000 – Less than 1500
1000 – manje od 1500
1000/100 mg bid and atazanavir.
Fosamprenavir
1000/100 mg bid)
1000/100 mg dvaput na
10000 doses
10000 doza
10000 doses
doza
10000 IU/1 ml
9000 IU/0,9 ml
10000 IU/1.0 ml
10000 IU/1 ml
10000 IU/1.0 ml
9000 IU/0,9 ml
10000 IU/1.0 ml
Eporatio
100ml
doza)
100x1 film-coated tablets
100x1 filmom obloženih tableta
100x1 film-coated tablets 28x1 film-coated tablets
28x1 filmom obloženih tableta
100x1 tablets (unit dose)
100x1 tableta (jedinična doza)
100×1 capsule
100×1 kapsula
100μg/kg 300 μg/kg
300 µg/kg
101 International Drive Pease International Tradeport 03801 Portsmouth
101 International Drive Pease International Tradeport 03801 Portsmouth Sjedinjene Američke Države
1010 Wien Austria
1010 Wien Austrija
10151 Tallinn
1186 DM Amstelveen
10151 Tallinn
Χαλάνδρι, 15231
102 tablets
102 tablete
102 tablets (17 blister strips with 6 tablets each)
102 tablete (17 blister traka s 6 tableta )
102 tablets (17 blister strips with 6 tablets each) Profender 150 mg/30 mg tablets for large dogs
102 tablete (17 blister traka s 6 tableta ) Profender 150 mg/ 30 mg tablete za velike pse
102 weeks there were 49 subjects still on infliximab treatment and among those, 30 (61%) were BASDAI 50 responders.
102. tjednu infliksimab je i dalje primalo 49 ispitanika, od kojih je 30 (61%) imalo klinički odgovor BASDAI 50.
102 weeks there were 80 subjects still on infliximab treatment and among those, 71 (89%) were ASAS 20 responders.
102. tjednu infliksimab je i dalje primalo 80 ispitanika, od kojih je 71 (89%) imalo klinički odgovor ASAS 20.
103.6 TCID50
103,.6 TCID50
1038 infusions were administered, 272 (in 16 patients) in the 3-week schedule and 766 (in 64 patients) in the 4-week schedule.
Primijenjeno je 1038 infuzija, 272 (kod 16 bolesnika) u 3-tjednom rasporedu i 766 (kod 64 bolesnika) u 4-tjednom rasporedu.
104.3 TCID50 10 3.1 TCID50
Pseći parvovorus tip 2b
1043 BW Amsterdam The Netherlands
1043 BW Amsterdam Nizozemska
1043EJ, Amsterdam The Netherlands
1043EJ, Amsterdam Nizozemska
105 21 Stockholm, Sweden
105 21 Stockholm, Švedska
105 mg (1.05 ml) twice daily
105 mg (1,05 ml) dva puta na dan
105 tablets
105 tableta
105.1 TCID50
105,1TCID50
105.3 TCID50
105,3TCID50
105.3 TCID50
106,6 TCID50